Menu Search
Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.85
  • Today's Change-0.10 / -3.39%
  • Shares traded2.68m
  • 1 Year change-52.89%
  • Beta1.6388
Data delayed at least 20 minutes, as of Nov 22 2024 17:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Shield Therapeutics PLC grew revenues 137.95% from 5.50m to 13.09m while net income improved from a loss of 49.79m to a smaller loss of 33.29m.
Gross margin34.65%
Net profit margin-173.18%
Operating margin-162.08%
Return on assets-81.80%
Return on equity-261.66%
Return on investment-136.41%
More ▼

Cash flow in GBPView more

In 2023, Shield Therapeutics PLC increased its cash reserves by 309.99%, or 10.55m. Cash Flow from Financing totalled 49.66m or 379.49% of revenues. In addition the company used 37.13m for operations while cash used for investing totalled 2.43m.
Cash flow per share-0.0459
Price/Cash flow per share--
Book value per share0.0007
Tangible book value per share-0.0216
More ▼

Balance sheet in GBPView more

Shield Therapeutics PLC has a Debt to Total Capital ratio of 97.36%, a higher figure than the previous year's 21.05%.
Current ratio1.05
Quick ratio0.8968
Total debt/total equity36.91
Total debt/total capital0.9736
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.